📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
24 announcements match the current filters (relevance ≥ 5).
Jupiter Life Line Q3 Income Up 9.8% to ₹365Cr; Dombivli Hospital Finished Ahead of Schedule
Jupiter Life Line Hospitals (JLHL) reported a 9.8% YoY growth in total income to ₹365.3 crore for Q3FY26, with a revised EBITDA of ₹85.4 crore. A major strategic milestone was achieved with the completion of the 500-bed Dombivli hospital in just 24 months, ahead of its Q1FY27 target. However, PAT for the quarter declined 18.7% YoY to ₹42.5 crore, largely due to a ₹6.4 crore statutory impact from New Labour Code changes and higher depreciation. Operational metrics remain robust, with ARPOB increasing to ₹66,800, although occupancy moderated to 61.9% due to capacity expansion.
Key Highlights
Dombivli hospital (500-bed capacity) completed ahead of schedule with Phase I operations starting Feb 2026.
9MFY26 Total Income rose 15.1% YoY to ₹1,111.9 crore, while EBITDA grew 15.2% to ₹249.2 crore.
Average Revenue Per Occupied Bed (ARPOB) grew significantly to ₹66,800 in 9MFY26 from ₹59,000 in 9MFY25.
Q3FY26 PAT of ₹42.5 crore was impacted by a ₹6.4 crore exceptional item related to New Labour Code changes.
Total bed capacity is projected to reach ~2,500 beds with upcoming projects in Pune and Mira-Bhayandar.
👀 What to Watch
Investors should focus on the long-term growth potential unlocked by the early operationalization of the Dombivli facility. While short-term margins were hit by regulatory costs, the strong ARPOB growth and aggressive capacity expansion plan justify a positive outlook.
Jupiter Life Line Q3 Revenue Up 10%; Dombivli Hospital Completed Ahead of Schedule
Jupiter Life Line Hospitals reported a 9.8% YoY growth in total income for Q3FY26 at Rs 365.3 crore, while 9MFY26 income rose 15.1% to Rs 1,111.9 crore. The company successfully completed its 500-bed Dombivli hospital ahead of schedule, with Phase I (200 beds) set for full clinical operations by February 18, 2026. Despite revenue growth, Q3 PAT declined 18.7% YoY to Rs 42.5 crore, primarily due to a Rs 6.4 crore impact from New Labour Code changes and higher depreciation. Operating metrics remain strong with ARPOB increasing to Rs 66,800 in 9MFY26 compared to Rs 59,000 in the previous year.
Key Highlights
9MFY26 Total Income grew 15.1% YoY to Rs 1,111.9 crore with EBITDA rising 15.2% to Rs 254 crore.
Dombivli hospital (500-bed capacity) completed in 24 months, ahead of the Q1FY27 target, with Rs 425 crore capex incurred.
Average Revenue Per Occupied Bed (ARPOB) improved significantly to Rs 66,800 in 9MFY26 from Rs 59,000 in 9MFY25.
Company plans to expand total capacity to ~2,500 beds by adding ~1,452 beds across Dombivli, Pune, and Mira-Bhayandar.
Q3 PAT was impacted by a one-time statutory charge of Rs 6.4 crore related to New Labour Code changes.
👀 What to Watch
Investors should view the early operationalization of the Dombivli facility as a significant growth catalyst for FY27. Monitor the occupancy ramp-up at the new facility and the management's ability to maintain high ARPOB levels amidst capacity expansion.
Jupiter Life Line Hospitals to Start 200-Bed Dombivli Facility on Feb 15, 2026
Jupiter Life Line Hospitals (JLHL) has announced the successful completion and commencement of operations at its new quaternary care hospital in Dombivli, Mumbai Metropolitan Region. The facility, which has a total planned capacity of 500 beds, will initially open with 200 operational beds following its inauguration on February 15, 2026. This project was a key milestone outlined in the company's 2023 IPO prospectus. The timely execution and licensing of this large-scale facility are expected to drive significant revenue growth in the coming fiscal years.
Key Highlights
New 500-bed quaternary care hospital completed in Dombivli, Mumbai Metropolitan Region
Initial phase of 200 beds to become operational starting February 15, 2026
All major requisite licenses for the facility have been successfully obtained
Expansion aligns with the long-term growth strategy disclosed in the September 2023 prospectus
👀 What to Watch
Investors should track the occupancy ramp-up and contribution to margins from this new facility over the next 2-4 quarters. The expansion significantly increases the company's total bed capacity and strengthens its presence in the high-demand Mumbai market.
Jupiter Life Line Hospitals Q3 PAT Dips 9.8% YoY to ₹44.3 Cr; Revenue Up 7.8%
Jupiter Life Line Hospitals reported a standalone revenue of ₹291.4 crore for Q3 FY26, marking a 7.8% growth compared to the same quarter last year. However, Profit After Tax (PAT) declined by 9.8% YoY to ₹44.3 crore, largely due to a one-time exceptional charge of ₹5.54 crore related to the implementation of New Labour Codes. On a sequential basis, the company saw a decline in both revenue and profit compared to Q2 FY26. For the nine-month period ended December 2025, the company maintained a stable PAT of ₹142.2 crore.
Key Highlights
Standalone Revenue from Operations grew 7.8% YoY to ₹2,913.98 million.
Standalone PAT decreased to ₹442.79 million from ₹491.07 million in Q3 FY25.
Recorded an exceptional expense of ₹55.44 million due to increased gratuity liability under New Labour Codes.
9M FY26 Revenue reached ₹8,852.01 million, a significant increase from ₹6,012.11 million in 9M FY25.
Basic EPS for the quarter stood at ₹6.75, down from ₹7.52 in the corresponding previous year quarter.
👀 What to Watch
Investors should note that the profit dip is partially due to a non-recurring exceptional item; however, the sequential (QoQ) decline in revenue and margins warrants a cautious watch on operational efficiency.
